Thanks to organizers for inviting!

📣We’re recruiting 1-2 Group Leaders! @NCMBMnews is looking for early-career researchers ready to establish their independent research groups! 🧬With an attractive start-up package, help us shape the future of molecular medicine in 🇳🇴 and be part of the @NordicEMBL! @embl

Congrats to our CRISPy fresh doctor 👏👏 Marcel McCullough for successfully defending his PhD thesis: 🧬✂️Combinatorial Gene Editing in Human Cells to Model Deficiencies of DNA Repair in Cancer Thx to committee members @CeronLab @LValleResearch and @DSzuts for great discussion!

Copenhagen is on a roll. It was ranked the safest major city in the world last year too. The food scene is sublime. Public transit phenomenal. So livable, so family friendly. Can't buy this mix of attributes for any amount of money in the US.

We observed that tRNA genes mutate like no tomorrow 👇

Join us at BRIC/Finsen -- start your lab at the University of Copenhagen!

Why care? This gives: -new resistance biomarkers (eg MAP2K4 in breast) -framework to compare pre/post-treatment genomes -warning about "driver genes" that are evol. relics Huge thanks to funders & bravo @Ahmed_IS_Khalil👏 ➡️Nice @IRBBarcelona write-up:

Bonus analysis: "cancer drivers" that are under selection in healthy tissues🧬. NOTCH1 (known) and ARID1A mutations promote clonal expansions w/o cancer transformation. Challenges assumptions about what makes a true driver - maybe some mutations are just along for the ride 4/5

Found 11 genes under therapy-associated selection - some expected (ESR1, EGFR) but surprises too: 💊PIK3CA selected in antiestrogen-treated 💊SMAD4 under pressure in 5-FU-treated 💊STK11 mutations with methotrexate Resistance often piggybacks onto existing oncogenic programs 3/5

Chemo changes mutation rates AND selection pressures - a confounding mess.🔥 DiffInvex cuts through this by using non-coding DNA as evolutionary baseline, separating signal (driver mutations) from noise (therapy-induced mutagenesis) in ~30 cancer types: 🔗 https://t.co/jITZB7oapr

🧵Ahmed’s @GenomeDataLab paper on evolution of chemotherapy resistance is out in @NatureComms! We developed DiffInvex - a method tracking how #cancer driver genes change under therapy, applied to ~10k genomes. Key insight: resistance often emerges through existing pathways. 1/5

Meanwhile in Europe: the Impossible Burger is still 100% illegal. Thank you, anti-GMO people, for protecting us from sustainable, humane and delicious plant-based burgers. 🙃

Grateful for the award of this collaborative project with Claus Sørensen group at BRIC, who will apply their awesome #CRISPR-Select method (Niu et al 2022 Nature Genetics) to introduce heterozygous edits into human cells. ➡️ https://t.co/IRq52LY2Ac

🧬 We aim to identify TSG #mutations that could be #targets for therapeutic inhibition - an idea supported by our recent finding that tumor suppressor #genes, paradoxically, can get copy number gains that drive cancer (Besedina & Supek 2024 Nature Comms https://t.co/k9Sj37pkrD)

Great news – we received funding from the Independent Research Fund Denmark @DFF_raad! 🧬We will study #cancer driver mutations in tumor suppressor genes. In particular, we will focus on so-called "dominant negative" mutations, by combining #genomics, #AI & CRISPR gene editing

Come and join us! We’re hiring a new Group Leader in Generative Biology at the @sangerinstitute Building AI models or the data to train them? Core funding of >$130M a year for a faculty of ~30. pls RT! https://t.co/skA0MAOTyZ https://t.co/cZ8i3TigJH

🚨 We have extended the deadline for submissions! 🚨 📅 New deadline: Feb 13, 2025, AoE - so you can finish just in time for Valentine's day 🥰 🔗 More details on our website (link in bio)

We are organising https://t.co/bmP3bmhJHq at#ICLR2025. Topics: RNA, DNA and cell LLMs, structure, modifications, correction, variant calling... Deadline: Feb 10th 2025 Time for revision: 1 month Accepted papers - the opportunity to be invited by Nature Methods for submission

Double PhD defense day in the lab 🤩 Congrats to our dr. Guille Palou @gpaloumarquez, fresh from the oven 🎊🥳 and similarly so our newly-minted dr. Ignasi Toledano @IgnasiToledano! Amazing defense both, bravo 👏👏

🧬🤖By bringing together machine learning & biology, we will explore how AI can address key challenges in nucleic acids research, such as structure prediction, understanding RNA/DNA interactions, and designing therapeutic molecules Our call for papers: ➡️ https://t.co/spCGf5hIAK